therapeutics-话题@MedSci

#therapeutics#

68篇内容 | 2540人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1350823, encodeId=180513508237d, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=2019 EHA：TG Therapeutics的抗CD47 / CD19双特异性抗体TG-1801临床前抗淋巴瘤作用显著, objectType=article, longId=168714, objectId=1c1a168e1418, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c1a168e1418, replyNumber=0, likeNumber=98, createdTime=2019-06-20, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c1a168e1418, moduleTitle=2019 EHA：TG Therapeutics的抗CD47 / CD19双特异性抗体TG-1801临床前抗淋巴瘤作用显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c1a168e1418)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350822, encodeId=e44c13508220b, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Vertex公司10亿美元收购Exonics Therapeutics，开发神经肌肉疾病的基因疗法, objectType=article, longId=167841, objectId=581816e84163, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=581816e84163, replyNumber=0, likeNumber=57, createdTime=2019-06-09, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=581816e84163, moduleTitle=Vertex公司10亿美元收购Exonics Therapeutics，开发神经肌肉疾病的基因疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=581816e84163)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350821, encodeId=121b1350821f0, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据, objectType=article, longId=167543, objectId=1bb016e5435e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bb016e5435e, replyNumber=0, likeNumber=52, createdTime=2019-06-04, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bb016e5435e, moduleTitle=2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bb016e5435e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350820, encodeId=2df31350820f5, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=AAN：Magenta Therapeutics的干细胞疗法MGTA-456的2期临床数据喜人, objectType=article, longId=165895, objectId=49e916589568, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49e916589568, replyNumber=0, likeNumber=60, createdTime=2019-05-13, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49e916589568, moduleTitle=AAN：Magenta Therapeutics的干细胞疗法MGTA-456的2期临床数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49e916589568)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350819, encodeId=98b413508191f, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Seres Therapeutics宣布与AstraZeneca合作探究肠道微生物与肿瘤免疫治疗的协同潜力, objectType=article, longId=162181, objectId=976c162181d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=976c162181d9, replyNumber=0, likeNumber=71, createdTime=2019-03-14, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=976c162181d9, moduleTitle=Seres Therapeutics宣布与AstraZeneca合作探究肠道微生物与肿瘤免疫治疗的协同潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=976c162181d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350818, encodeId=2c6113508184a, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=OSE Immunotherapeutics的免疫检查点抑制剂： SIRPα单抗BI 765063获批在晚期实体瘤患者中进行1期临床研究, objectType=article, longId=161788, objectId=2b6a161e88d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b6a161e88d5, replyNumber=0, likeNumber=78, createdTime=2019-03-08, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b6a161e88d5, moduleTitle=OSE Immunotherapeutics的免疫检查点抑制剂： SIRPα单抗BI 765063获批在晚期实体瘤患者中进行1期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b6a161e88d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350817, encodeId=c012135081e99, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Syncona的Nightstar Therapeutics将以8.77亿美元被Biogen收购, objectType=article, longId=161654, objectId=1df1161654bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1df1161654bc, replyNumber=0, likeNumber=63, createdTime=2019-03-06, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1df1161654bc, moduleTitle=Syncona的Nightstar Therapeutics将以8.77亿美元被Biogen收购, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1df1161654bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350816, encodeId=2360135081697, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=2019年ASCO-SITC会议：Nektar Therapeutics公布新型Toll样受体激动剂NKTR-262的剂量递增研究, objectType=article, longId=161610, objectId=ccc41616101d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccc41616101d, replyNumber=0, likeNumber=0, createdTime=2019-03-06, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccc41616101d, moduleTitle=2019年ASCO-SITC会议：Nektar Therapeutics公布新型Toll样受体激动剂NKTR-262的剂量递增研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccc41616101d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350815, encodeId=6d5c135081517, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=罗氏以43亿美元收购基因治疗公司Spark Therapeutics, objectType=article, longId=161102, objectId=128b16110211, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=128b16110211, replyNumber=0, likeNumber=78, createdTime=2019-02-27, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=128b16110211, moduleTitle=罗氏以43亿美元收购基因治疗公司Spark Therapeutics, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=128b16110211)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350814, encodeId=ee94135081414, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Aquestive Therapeutics收到美国食品和药物管理局（FDA）关于他达拉非口服薄膜的完整回复信, objectType=article, longId=153908, objectId=b841153908a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b841153908a0, replyNumber=0, likeNumber=112, createdTime=2018-11-21, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b841153908a0, moduleTitle=Aquestive Therapeutics收到美国食品和药物管理局（FDA）关于他达拉非口服薄膜的完整回复信, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b841153908a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350813, encodeId=46f413508137b, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=INSYS Therapeutics肾上腺素鼻腔喷雾获得FDA快速通道资格认定用于治疗严重过敏反应, objectType=article, longId=147908, objectId=868114e90896, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=868114e90896, replyNumber=0, likeNumber=57, createdTime=2018-09-02, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=868114e90896, moduleTitle=INSYS Therapeutics肾上腺素鼻腔喷雾获得FDA快速通道资格认定用于治疗严重过敏反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=868114e90896)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350812, encodeId=d6371350812e9, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Unum Therapeutics宣布研究性新药（IND）申请：抗体偶联T细胞受体（ACTR）细胞疗法和曲妥珠单抗联合治疗HER2阳性晚期癌症, objectType=article, longId=146626, objectId=e59d146626ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e59d146626ef, replyNumber=0, likeNumber=94, createdTime=2018-08-16, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e59d146626ef, moduleTitle=Unum Therapeutics宣布研究性新药（IND）申请：抗体偶联T细胞受体（ACTR）细胞疗法和曲妥珠单抗联合治疗HER2阳性晚期癌症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e59d146626ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350811, encodeId=c7241350811c5, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=FDA拒绝INSYS Therapeutics的丁丙诺啡舌下喷雾治疗急性疼痛, objectType=article, longId=145381, objectId=2f6e14538120, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f6e14538120, replyNumber=0, likeNumber=68, createdTime=2018-07-30, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f6e14538120, moduleTitle=FDA拒绝INSYS Therapeutics的丁丙诺啡舌下喷雾治疗急性疼痛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f6e14538120)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350810, encodeId=b3dc135081056, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=德琪医药与Karyopharm Therapeutics正式启动战略合作，正式进军血液肿瘤领域, objectType=article, longId=139417, objectId=2cad13941ef3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cad13941ef3, replyNumber=0, likeNumber=41, createdTime=2018-05-31, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cad13941ef3, moduleTitle=德琪医药与Karyopharm Therapeutics正式启动战略合作，正式进军血液肿瘤领域, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cad13941ef3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350809, encodeId=fdfa135080904, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=英国的Enterprise Therapeutics公司筹集了2900万英镑用于推进呼吸道疾病的实验疗法, objectType=article, longId=135416, objectId=5056135416f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5056135416f5, replyNumber=0, likeNumber=56, createdTime=2018-04-17, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5056135416f5, moduleTitle=英国的Enterprise Therapeutics公司筹集了2900万英镑用于推进呼吸道疾病的实验疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5056135416f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350808, encodeId=64ed1350808a7, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=vTv Therapeutics公司阿尔茨海默症候选药物临床试验失败, objectType=article, longId=135139, objectId=8b85135139e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b85135139e4, replyNumber=0, likeNumber=58, createdTime=2018-04-14, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b85135139e4, moduleTitle=vTv Therapeutics公司阿尔茨海默症候选药物临床试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b85135139e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350807, encodeId=e790135080ed3, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Alexion收购Wilson Therapeutics公司获得威尔逊病的治疗药物, objectType=article, longId=135056, objectId=850513505659, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=850513505659, replyNumber=0, likeNumber=60, createdTime=2018-04-13, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=850513505659, moduleTitle=Alexion收购Wilson Therapeutics公司获得威尔逊病的治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=850513505659)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350806, encodeId=4373135080683, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Nucleic Acid Therapeutics：改善mRNA治疗有效性的3点建议, objectType=article, longId=134136, objectId=9f49134136a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f49134136a3, replyNumber=0, likeNumber=0, createdTime=2018-04-04, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f49134136a3, moduleTitle=Nucleic Acid Therapeutics：改善mRNA治疗有效性的3点建议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f49134136a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350805, encodeId=c77d1350805ff, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=勃林格殷格翰携手MiNA Therapeutics公司共同研发肝纤维化疾病新型治疗手段, objectType=article, longId=120149, objectId=7e731201496a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e731201496a, replyNumber=0, likeNumber=65, createdTime=2017-11-17, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e731201496a, moduleTitle=勃林格殷格翰携手MiNA Therapeutics公司共同研发肝纤维化疾病新型治疗手段, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e731201496a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350804, encodeId=11fc135080440, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=AMBROSUS与TREK THERAPEUTICS合作开发基于区块链的解决方案, objectType=article, longId=111383, objectId=00311113835a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00311113835a, replyNumber=0, likeNumber=68, createdTime=2017-09-01, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00311113835a, moduleTitle=AMBROSUS与TREK THERAPEUTICS合作开发基于区块链的解决方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00311113835a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

therapeutics

2020-05-29

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

2019 EHA：TG Therapeutics的抗CD47 / CD19双特异性抗体TG-1801临床前抗淋巴瘤作用显著

2019-06-20

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Vertex公司10亿美元收购Exonics Therapeutics，开发神经肌肉疾病的基因疗法

2019-06-09

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据

2019-06-04

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

AAN：Magenta Therapeutics的干细胞疗法MGTA-456的2期临床数据喜人

2019-05-13

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Seres Therapeutics宣布与AstraZeneca合作探究肠道微生物与肿瘤免疫治疗的协同潜力

2019-03-14

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

OSE Immunotherapeutics的免疫检查点抑制剂： SIRPα单抗BI 765063获批在晚期实体瘤患者中进行1期临床研究

2019-03-08

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Syncona的Nightstar Therapeutics将以8.77亿美元被Biogen收购

2019-03-06

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

2019年ASCO-SITC会议：Nektar Therapeutics公布新型Toll样受体激动剂NKTR-262的剂量递增研究

2019-03-06

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

罗氏以43亿美元收购基因治疗公司Spark Therapeutics

2019-02-27

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Aquestive Therapeutics收到美国食品和药物管理局（FDA）关于他达拉非口服薄膜的完整回复信

2018-11-21

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

INSYS Therapeutics肾上腺素鼻腔喷雾获得FDA快速通道资格认定用于治疗严重过敏反应

2018-09-02

仁心济世 (审核中...)

前往app查看评论内容

#therapeutics#

Unum Therapeutics宣布研究性新药（IND）申请：抗体偶联T细胞受体（ACTR）细胞疗法和曲妥珠单抗联合治疗HER2阳性晚期癌症

2018-08-16

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

FDA拒绝INSYS Therapeutics的丁丙诺啡舌下喷雾治疗急性疼痛

2018-07-30

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

德琪医药与Karyopharm Therapeutics正式启动战略合作，正式进军血液肿瘤领域

2018-05-31

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

英国的Enterprise Therapeutics公司筹集了2900万英镑用于推进呼吸道疾病的实验疗法

2018-04-17

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

vTv Therapeutics公司阿尔茨海默症候选药物临床试验失败

2018-04-14

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Alexion收购Wilson Therapeutics公司获得威尔逊病的治疗药物

2018-04-13

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Nucleic Acid Therapeutics：改善mRNA治疗有效性的3点建议

2018-04-04

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

勃林格殷格翰携手MiNA Therapeutics公司共同研发肝纤维化疾病新型治疗手段

2017-11-17

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

AMBROSUS与TREK THERAPEUTICS合作开发基于区块链的解决方案

2017-09-01

科室
- - 订阅+
  - 更多科室
工具
服务